|
1
|
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.
|
Cancer Res
|
2005
|
2.67
|
|
2
|
Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice.
|
Carcinogenesis
|
2009
|
1.85
|
|
3
|
The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.
|
Cancer Res
|
2007
|
1.81
|
|
4
|
The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.
|
Clin Cancer Res
|
2003
|
1.53
|
|
5
|
The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.
|
Clin Cancer Res
|
2006
|
1.40
|
|
6
|
Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.
|
Cancer Res
|
2003
|
1.32
|
|
7
|
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.
|
Clin Cancer Res
|
2008
|
1.28
|
|
8
|
Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.
|
Cancer Prev Res (Phila)
|
2010
|
1.19
|
|
9
|
Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets.
|
J Med Chem
|
2004
|
1.09
|
|
10
|
Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease.
|
Antioxid Redox Signal
|
2012
|
1.09
|
|
11
|
A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin.
|
Cancer Res
|
2008
|
1.06
|
|
12
|
Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice.
|
Cancer Prev Res (Phila)
|
2009
|
1.03
|
|
13
|
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
|
Clin Cancer Res
|
2006
|
1.03
|
|
14
|
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.
|
Mol Cancer Ther
|
2008
|
0.98
|
|
15
|
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
|
Cell Cycle
|
2015
|
0.98
|
|
16
|
Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A.
|
Bioorg Med Chem Lett
|
2006
|
0.97
|
|
17
|
CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.
|
Cancer Prev Res (Phila)
|
2011
|
0.95
|
|
18
|
The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice.
|
Cancer Prev Res (Phila)
|
2012
|
0.92
|
|
19
|
A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland.
|
Clin Cancer Res
|
2007
|
0.92
|
|
20
|
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities.
|
Mol Cancer Ther
|
2007
|
0.90
|
|
21
|
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
|
Clin Cancer Res
|
2002
|
0.89
|
|
22
|
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
|
Cancer Res
|
2004
|
0.88
|
|
23
|
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
|
Carcinogenesis
|
2012
|
0.85
|